Next 60 daysI see a stagnant share price. I project that the pitch for the reverse will be made at the shareholders meeting and this same dead share price, lack of volume and no US interest used at the justification to do so. There will be no mention of any initiatives they have taken to move the SP and prperly value this approval stage cancer therapy and shareholders will be forced to eat the "under the radar" program and vote to support the 15 for 1. In celebration of this victory over shareholders 10 mil more 37 cent management options will be minted.